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Please Stand Up?*
Edward A. Gill, MD,y Jeanne E. Poole, MDzI n 1925, Dr. Carl J. Wiggers demonstrated thatpacing from the canine left ventricle (LV)improved acute hemodynamics (1). The advent
of pacing catheters delivered by the coronary sinus
allowed practical use and exploration of LV or biven-
tricular (BiV) pacing for improving heart failure (HF)
symptoms. By 2000, BiV pacing was performed in 17
patients with New York Heart Association (NYHA)
functional class III to IV HF and electrical dyssyn-
chrony (electrocardiography [ECG] QRS duration
>140 ms) followed for 3 months. The results demon-
strated improvements in serial echocardiographic
measures of ejection fraction (EF), mitral insufﬁ-
ciency, dP/dt, and LV volumes, which regressed
following termination of BiV pacing (2).
Since this trial, over 4,000 NHYA functional class III
to IV and over 4,500 NYHA functional class I to II pa-
tients have been evaluated in randomized controlled
trials of cardiac resynchronization therapy (CRT), with
4 consistent themes: 1) most patients improve clini-
cally, and roughly 25% are “nonresponders” (the same
failure rate observed for contemporary pharmacolog-
ical HF therapy); 2) most trials used a wide QRS
duration (QRSd), although with variable cutoffs
($120, $130, or $150 ms) as the measure of electrical
dyssynchrony; 3) echocardiographic measures of*Editorials published in the Journal of the American College of Cardiology
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enrollment strategy; and 4) patients with narrow QRSd
(#120 or #130 ms, especially with non–left bundle
branch block [LBBB]), show poor response to CRT in
limited studies. Mortality was not the primary
endpoint in any of the trials; all combined endpoints
emphasized symptomatic and functional improve-
ments. Decreased mortality as a secondary endpoint
was notably seen in the COMPANION (Comparison of
Medical Therapy, Pacing, and Deﬁbrillation in Heart
Failure) and CARE-HF (Cardiac Resynchronization–
Heart Failure) trials (3,4).
Thus, QRSd was the foundational enrollment cri-
terion for the CRT trial. Although few patients with a
right bundle branch block were enrolled, the obser-
vation that patients with either a right bundle branch
block or a nonspeciﬁc intraventricular conduction
delay demonstrate inferior outcomes compared with
those with LBBB has been made more recently from
the 3 trials (REVERSE [Resynchronization Reverses
Remodeling in Systolic Left Ventricular Dysfunction]
[5], MADIT-CRT [Multicenter Automatic Deﬁbrillator
Implantation Trial with Cardiac Resynchroniza-
tion Therapy] [6], and RAFT [Resynchronization-
Deﬁbrillation for Ambulatory Heart Failure Trial
[7]) that enrolled NYHA functional class I to II pa-
tients. All 3 showed beneﬁt of CRT–implantable
cardioverter-deﬁbrillator therapy compared with
implantable cardioverter-deﬁbrillator alone on the
basis of outcomes of decreased HF events and com-
posite endpoints and found that QRSd ($160 ms in
RAFT [8,9] and $150 in the MADIT-CRT) and QRS
morphology, speciﬁcally LBBB, were predictive of a
superior outcome. This morphology ﬁnding from
MADIT-CRT led the U.S. Food and Drug Administra-
tion to restrict device labeling for NYHA functional
class I and II HF patients with LBBB and inﬂuenced
reconﬁguration of the U.S. and European guidelines
to emphasize QRS morphology beyond QRSd.
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643Finally, 3 major trials have addressed narrow QRSd
dyssynchrony (10–12). The largest, EchoCRT (Echo-
cardiography Guided Cardiac Resynchronization
Therapy) (12), concluded that narrow QRS dyssyn-
chrony, despite evidence of mechanical dyssyn-
chrony by echocardiography, does not respond
favorably to CRT. In EchoCRT (NYHA functional class
III to IV, EF #35%, LV end-diastolic diameter $55
mm, QRSd #130 ms, and echocardiographic evidence
of dyssynchrony), there was a nonsigniﬁcant trend
toward worsening in patients randomized to CRT on
the primary composite endpoint (death or ﬁrst hos-
pitalization) and clearly more deaths (a secondary
endpoint: 11.1% vs. 6.4%; p ¼ 0.02).SEE PAGE 631In this issue of the Journal, Risum et al. (13)
attempt to transcend even QRS morphology to reﬁne
selection of “optimal” CRT candidates. In their study,
234 patients with QRSd $120, LVEF #35%, NYHA
functional class II to IV, and an LBBB pattern on ECG
underwent an evaluation of LV dyssynchrony by
longitudinal strain imaging utilizing 2-dimensional
speckle tracking echocardiography (2DSE). Instead
of using the time-to-peak principle, as in previous
studies to predict response to CRT, most notably
PROSPECT (Results of the Predictors of Response to
CRT) (14) and EchoCRT (12), the authors used a pre-
speciﬁed longitudinal strain pattern recognition of
LBBB. Subjects were considered to have a true LBBB if
all 3 of the following echocardiographic characteris-
tics were present: 1) “early” shortening of at least 1
basal or midventricular segment in the septal wall;
2) early septal peak shortening (within the ﬁrst 70% of
ejection phase); and 3) lateral wall peak shortening
after aortic valve closure. The authors conclude that
this method is superior to previously used methods in
that the interobserver and intraobserver variability
was excellent, with kappa agreement scores of 1.0 and
0.87. In contrast, intraobserver and interobserver
agreement in the PROSPECT trial, as measured by the
coefﬁcient of variation, was poor (as high as 16% and
72%, respectively). Risum et al. (13) found that,
despite an LBBB on ECG deﬁned by conventional ECG
criteria, more than one-third of patients did not show
the 2DSE pattern of “true” LBBB contraction. During a
4-year follow-up, patients with the LBBB contraction
pattern by 2DSE had fewer composite events (death,
transplant, or need for LV assist device placement)
than those without an echocardiographically-deﬁned
LBBB contraction pattern (14% vs. 40%; hazard
ratio: 3.57; 95% conﬁdence interval: 2.00 to 6.66;
p < 0.001). The c-statistic for estimating riskincreased from 0.63 to 0.70 when adding the LBBB
pattern by 2DSE (p ¼ 0.02).
Also notable was that only 30% of patients with a
QRSd between 120 and 140 ms had LBBB contraction
using 2DSE, compared with 65% of patients with
QRSd >140 ms. The LBBB pattern of contraction by
2DSE was also superior even to the “strict” ECG LBBB
pattern recently described by Strauss et al. (15).
Finally, when taking multivariable models into ac-
count, comparing the LBBB pattern of contraction by
2DSE was superior to older time-to-peak methods
using tissue Doppler imaging, longitudinal and radial
strain, and tissue Doppler imaging opposing wall
dyssynchrony.
The study by Risum et al. (13) emphasizes the
limitations of conventional ECG-deﬁned LBBB in
detection of true mechanical dyssynchrony and pro-
vides initial evidence that a combination of electrical
dyssynchrony by ECG and echocardiography-deﬁned
LBBB to detect mechanical dyssynchrony could
enhance the selection process for CRT.
However, HF patients are complex, and it is not
surprising that many with apparent LBBB will not
have mechanical dyssynchrony as deﬁned by the
echocardiographic measures used in this study. The
variable presence of scar versus viable myocardium,
including in the lateral wall, affects contraction pat-
terns. The lateral wall may not be the latest myocar-
dial segment activated, such that resynchronization
may be achieved by alternatively locating the LV lead.
Gold et al. (16) have used the QLV measurement to
allow consideration of such variables for identiﬁca-
tion of the optimum LV pacing site at the time of CRT
implant.
Thus, on the basis of the authors’ ﬁndings, one
might conclude that deﬁning “true” LBBB by echo-
cardiography is the ﬁnal answer for CRT selection.
Should we believe this? Such patients may be “super-
responders,” as observed in a MADIT-CRT substudy,
but many more patients may beneﬁt from CRT.
Approximately 80% of MADIT-CRT LBBB patients
were responders or super-responders, deﬁned by
LVEF improvements or the primary combined outcome
of nonfatal HF events or all-cause mortality (17).
A more signiﬁcant caveat is whether the ﬁndings of
Risum et al. (13) are generalizable to the global practice
of echocardiography. Use of strain is expanding, and it
is close to disseminated use. For the immediate future,
strain will be mainly used in academic laboratories
for research purposes. Even frequent users may
have some difﬁculty reproducing the authors’ LBBB
ﬁndings. Late lateral wall contraction (after aortic
valve closure) in particular can be a nonspeciﬁc
ﬁnding, seen in 31% of segments from 20 normal
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644young patients (18). Additionally, the early septal peak
shortening of 70% is unlikely to be precisely quanti-
ﬁed. Finally, strain measurements have signiﬁcantly
varied between different vendors of echocardiography
machines. The good news is: 1) the current study used
only 1 type of echocardiography machine; 2) the vari-
ation has been signiﬁcantly reduced (19); and 3) deﬁ-
nition of LBBB by 2DSE is based more on timing than
percent strain, much less subject to intervendor
variation.
Thus, putting the clinical implications of the study
by Risum et al. (13) into ﬁnal context gives us pause.
We applaud the authors for making a signiﬁcant
advancement for the credibility of echocardiography
in determination of mechanical dyssynchrony. But,did the real LBBB stand up, or is the “truth” still
untold (20) (except to Alex Trebek).
As the authors also suggest, we believe that
conﬁrmation by a randomized trial that included not
only the hard endpoints of mortality and HF events,
but also the standard measures of quality of life,
LV volumes, and functional measurements such as
6-min walk or VO2 would best serve adoption of
this approach by clinicians and the guidelines
committees.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Edward A. Gill, University of Washington, Harborview
Medical Center, Box 359748, Seattle, Washington
98104. E-mail: eagill@uw.edu.RE F E RENCE S1. Wiggers CJ. The muscular reactions of the
mammalian ventricles to artiﬁcial surface stimuli.
Am J Physiol 1925;73:346–78.
2. Yu CM, Fung WH, Lin H, et al. Predictors of left
ventricular reverse remodeling after cardiac
resynchronization therapy for heart failure sec-
ondary to idiopathic dilated or ischemic cardio-
myopathy. Am J Cardiol 2003;91:684–8.
3. Bristow MR, Saxon LA, Boehmer J, et al., for the
Comparison of Medical Therapy, Pacing, and
Deﬁbrillation in Heart Failure (COMPANION)
Investigators. Cardiac-resynchronization therapy
with or without an implantable deﬁbrillator in
advanced chronic heart failure. N Engl J Med
2004;350:2140–50.
4. Cleland JGF, Daubert JC, Erdmann E, et al., for
the Cardiac Resynchronization—Heart Failure
(CARE-HF) Study Investigators. The effect of
cardiac resynchronization on morbidity and mor-
tality in heart failure. N Engl J Med 2005;352:
1539–49.
5. Daubert C, Gold MR, Abraham WT, et al. Pre-
vention of disease progression by cardiac
resynchronization therapy in patients with
asymptomatic or mildly symptomatic left ventric-
ular dysfunction: insights from the European
cohort of the REVERSE (Resynchronization Re-
verses Remodeling in Systolic Left Ventricular
Dysfunction) trial. J Am Coll Cardiol 2009;54:
1837–46.
6. Moss AJ, Hall WJ, Cannom DS, et al., for the
MADIT-CRT Trial Investigators. Cardiac-resynch-
ronization therapy for the prevention of heart-
failure events. N Engl J Med 2009;361:1329–38.
7. Tang ASL, Wells GA, Talajic M, et al., for the
Resynchronization–Deﬁbrillation for Ambulatory
Heart Failure Trial (RAFT) Investigators. Cardiac-resynchronization therapy for mild-to-moderate
heart failure. N Engl J Med 2010;363:2385–95.
8. Gold MR, Thébault C, Linde C, et al. Effect of
QRS duration and morphology on cardiac
resynchronization therapy outcomes in mild heart
failure: results from the Resynchronization Re-
verses Remodeling in Systolic Left Ventricular
Dysfunction (REVERSE) study. Circulation 2012;
126:822–9.
9. Birnie DH, Ha A, Higginson L, et al. Impact of
QRS morphology and duration on outcomes after
cardiac resynchronization therapy: results from
the Resynchronization-Deﬁbrillation for Ambula-
tory Heart Failure Trial (RAFT). Circ Heart Fail
2013;6:1190–8.
10. Muto C, Solimene F, Gallo P, et al.
A randomized study of cardiac resynchronization
therapy deﬁbrillator versus dual-chamber im-
plantable cardioverter-deﬁbrillator in ischemic
cardiomyopathy with narrow QRS: the NARROW-
CRT study. Circ Arrhythm Electrophysiol 2013;6:
538–45.
11. Beshai JF, Grimm RA, Nagueh SF, et al.,
for the RethinQ Study Investigators. Cardiac-
resynchronization therapy in heart failure with
narrow QRS complexes. N Engl J Med 2007;357:
2461–71.
12. Ruschitzka F, Abraham WT, Singh JP, et al., for
the EchoCRT Study Group. Cardiac-resynchroni-
zation therapy in heart failure with a narrow QRS
complex. N Engl J Med 2013;369:1395–405.
13. Risum N, Tayal B, Hansen TF, et al. Identiﬁca-
tion of typical left bundle branch block contrac-
tion by strain echocardiography is additive to
electrocardiography in prediction of long-term
outcome after cardiac resynchronization therapy.
J Am Coll Cardiol 2015;66:631–41.14. Chung ES, Leon AR, Tavazzi L, et al. Results of
the Predictors of Response to CRT (PROSPECT)
trial. Circulation 2008;117:2608–16.
15. Strauss DG, Selvester RH, Wagner GS. Deﬁning
left bundle branch block in the era of cardiac
resynchronization therapy. Am J Cardiol 2011;107:
927–34.
16. Gold MR, Birgersdotter-Green U, Singh JP,
et al. The relationship between ventricular elec-
trical delay and left ventricular remodelling with
cardiac resynchronization therapy. Eur Heart J
2011;32:2516–24.
17. Hsu JC, Solomon SD, Bourgoun M, et al. Pre-
dictors of super-response to cardiac resynchroni-
zation therapy and associated improvement in
clinical outcome: the MADIT-CRT (Multicenter
Automatic Deﬁbrillator Implantation Trial with
Cardiac Resynchronization Therapy) study. J Am
Coll Cardiol 2012;59:2366–73.
18. Voigt JU, Lindenmeier G, Exner B, et al. Inci-
dence and characteristics of segmental post-
systolic longitudinal shortening in normal, acutely
ischemic, and scarred myocardium. J Am Soc
Echocardiogr 2003;16:415–23.
19. Yang H, Marwick TH, Fukuda N, et al. Improve-
ment in strain concordance between two major
vendors after the strain standardization initiative.
J Am Soc Echocardiogr 2015;28:642–8.e7.
20. Wikipedia. To Tell the Truth. Available at:
https://en.wikipedia.org/wiki/To_Tell_the_Truth.
Accessed June 22, 2015.
KEY WORDS cardiac resynchronization
therapy, deﬁbrillators, echocardiography,
electrocardiography, heart assist devices,
heart failure, implantable
